-

New Study Shows Effectiveness of Polyester Swabs and Saline Transportation for COVID-19 Testing, Improving Testing Efficiency and Flexibility, and Protecting Health Care Workers

  • Widely available polyester swabs and saline transportation are safe and reliable alternatives to foam swabs and viral transport media
  • New study builds on previously reported, less invasive nasal-testing procedure that reduces exposure for health care workers, preserves personal protective equipment and is better tolerated by patients
  • The FDA has updated its guidance based on this study to allow polyester swabs and saline transport media to be used for COVID-19 testing

MINNETONKA, Minn.--(BUSINESS WIRE)--A study led by UnitedHealth Group (NYSE: UNH) Research & Development and The Everett Clinic, part of Optum, revealed alternative swab materials and commonly available saline are effective for COVID-19 testing, providing more options for sample collection. These new findings, in conjunction with nasal sampling, allow for greater flexibility in obtaining samples, reduce the risk of infection to clinicians in collecting samples and can reduce the need for clinicians to use protective equipment.

The Food and Drug Administration (FDA) has updated its guidance based on the UnitedHealth Group research, allowing patients nationwide to use polyester swabs instead of foam swabs and store tested swab samples in saline rather than traditional viral transport media. With ongoing challenges in obtaining test supplies around the world, proving the effectiveness of alternative materials introduces much-needed flexibility and increased capacity into COVID-19 testing.

“While foam nasal swabs can be used effectively, they are not as readily available as polyester swabs. Additionally, the supply of traditional viral transport media is limited,” said study lead Dr. Yuan-Po Tu, an infectious disease expert at The Everett Clinic, part of Optum. “This study further refines UnitedHealth Group and OptumCare research showing how a simple, patient-administered test can effectively and efficiently test for COVID-19 infections.”

With medical supplies limited and COVID-19 test kits not yet broadly available, expanding swab types and swab-transport processes are crucial to providing more options in efforts to detect COVID-19.

The traditional COVID-19 test regimen required a trained health care worker to collect samples from deep inside the patient’s nasal cavity using a nasopharyngeal swab. The process required the use of personal protective equipment, was uncomfortable for the patient and put unnecessary strain on the health care supply chain by requiring a specialized swab and specialized viral transport media. The patient-administered testing method is significantly less invasive, allowing patients to swab the front part of the nostril and mid-nose.

“We are leading several significant R&D projects on COVID-19,” said Ken Ehlert, chief scientific officer of UnitedHealth Group, parent company of Optum. “This research study substantially improves COVID-19 testing capacity by demonstrating that alternative materials and techniques can be used. Our second study at The Everett Clinic builds on our previous research that showed patients can successfully self-administer nasal swabs for COVID-19 testing. We are grateful to be partnering with a broad range of collaborators to advance community and national response efforts against COVID-19.”

The study was conducted in partnership with the Bill & Melinda Gates Foundation.

“We’re committed to working with partners to identify the simplest, most accessible solutions to obtaining an accurate COVID-19 test result,” said Dan Wattendorf, director of Innovative Technology Solutions, Bill & Melinda Gates Foundation. “Today’s FDA approval of spun polyester swabs for self-administered sample collection is another big step forward because these swabs can be readily manufactured and scaled, helping to overcome current shortages. The ultimate goal is to ensure that testing swabs will be readily available for self-administered sample collection at healthcare facilities, in workplaces and at home.”

About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping to make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Contacts

Eric Hausman
952-936-3963
Eric.Hausman@uhg.com

UnitedHealth Group

NYSE:UNH

Release Versions

Contacts

Eric Hausman
952-936-3963
Eric.Hausman@uhg.com

More News From UnitedHealth Group

Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors

--(BUSINESS WIRE)--Dr. Scott Gottlieb, former U.S. Food and Drug Administration (FDA) commissioner, is joining UnitedHealth Group’s (NYSE: UNH) Board of Directors, effective immediately. Dr. Gottlieb, 53, served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront t...

UnitedHealth Group Recommends Shareholders Reject "Mini-Tender" Offer by Tutanota

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (Tutanota) to purchase up to 175,000 shares of UnitedHealth Group’s common stock, representing significantly less than 1% of UnitedHealth Group’s common stock outstanding. The offer price of $325.00 per share is conditioned on, among other things, the closing price per share of UnitedHealth Group’s common stock exceeding $325.00 per share on the l...

UnitedHealth Group Announces Leadership Transition

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty’s decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company’s Board of Directors and Witty will serve as a senior adviser to Hemsley. “We are grateful for Andrew’s stewardship of UnitedHealth Group, especially during some of the most cha...
Back to Newsroom